Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Merck Ltd to Focus on Cancer, Emergency Care
March 29, 2004
- Meet the Leaders (31)
March 22, 2004
- Banyu to "Seriously Go After the Japanese Market": Mr Hirate
March 22, 2004
- Annual Business Results
March 22, 2004
- Aiming to Be a "Global Mega-player" via Merger: Dr Aoki of Fujisawa
March 22, 2004
- WORLD NEWS IN BREIF
March 22, 2004
- Eisai Seeks Efficiency, Not Scale: Mr Naito
March 22, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 22, 2004
- Pfizer Japan Aims to Boost MR Productivity by 50% in 5 Years: Mr Bootes
March 22, 2004
- OTC NEWS IN BRIEF
March 22, 2004
- BULLETIN
March 22, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 22, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 22, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 22, 2004
- REGULATORY NEWS IN BRIEF
March 22, 2004
- Impact of NHI Price Revisions Ranges from 3% to 7%
March 22, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
March 22, 2004
- New NHI Prices Gazetted on March 5
March 22, 2004
- BUSINESS NEWS IN BRIEF
March 22, 2004
- Japan CRO Association Holds 10th Anniversary Symposium
March 22, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…